• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The American heart journal >Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: a subgroup analysis of the randomized, controlled CERTIFY study.
【24h】

Certoparin versus unfractionated heparin to prevent venous thromboembolic events in patients hospitalized because of heart failure: a subgroup analysis of the randomized, controlled CERTIFY study.

机译：Certoparin与普通肝素预防因心力衰竭住院的患者的静脉血栓栓塞事件：随机对照CERTIFY研究的亚组分析。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Despite the elevated risk for developing venous thromboembolic events in patients with heart failure, there are no randomized, double-blind, controlled trial data on the comparison of low-molecular-weight heparin with unfractionated heparin (UFH) in this patient population. METHODS: This was a subgroup analysis of the CERTIFY trial, which included 3,239 nonsurgical, acutely ill medical patients 70 years or older. Patients were randomized to receive 3,000-U anti-Xa certoparin once daily or 5,000-IU UFH 3 times a day. The analysis was performed on a subgroup of 542 patients diagnosed with heart failure at hospital admission. RESULTS: Patients with heart failure differed from patients without heart failure in that they were more likely using antiplatelets (67.2% vs 48.9%; P < .0001) and had a lower glomerular filtration rate (8.0% vs 5.5%;
机译：背景：尽管心力衰竭患者发生静脉血栓栓塞事件的风险较高，但尚无关于该患者人群中低分子量肝素与普通肝素（UFH）比较的随机，双盲，对照试验数据。方法：这是CERTIFY试验的亚组分析，其中包括3,239名70岁以上的非手术，急性病医疗患者。患者随机接受每日一次3,000-U抗Xa certoparin或每天3次接受5,000-IU UFH。对入院时被诊断为心力衰竭的542名患者的亚组进行了分析。结果：心力衰竭患者与非心力衰竭患者的区别在于，他们使用抗血小板的可能性更高（67.2％比48.9％; P <.0001），肾小球滤过率更低（8.0％比5.5％;

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号